LB Pharmaceuticals Inc Common Stock(LBRX)Earnings, Financials & Key Ratios
LBRX•NASDAQ
$32.00
$113M mkt cap·Price updated May 6, 2026
AboutClinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.Show more
- Revenue$0
- EBITDA-$65M-469.3%
- Net Income-$63M-905.6%
- EPS (Diluted)-17.83-907.3%
LBRX Key Insights
LB Pharmaceuticals Inc Common Stock (LBRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LBRX Price & Volume
LB Pharmaceuticals Inc Common Stock (LBRX) stock price & volume — 10-year historical chart
Loading chart...
LBRX Growth Metrics
LB Pharmaceuticals Inc Common Stock (LBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-79.41%
5 Years-79.41%
3 Years-79.41%
Last Year-189.35%
LBRX Recent Earnings
LB Pharmaceuticals Inc Common Stock (LBRX) EPS & revenue vs analyst estimates — last 2 quarters
●Beat EPS 0/2 qtrs (0%)
Q2 2026Latest
Mar 26, 2026EPS
$0.45
Est $0.45
+0.0%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.61
Est $0.57
-7.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.45vs $0.45+0.0% | — |
| Q4 2025 | Nov 6, 2025 | $0.61vs $0.57-7.0% | — |
Based on last 2 quarters of dataView full earnings history →
LBRX Peer Comparison
LB Pharmaceuticals Inc Common Stock (LBRX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INTR | 2.54B | 7.84 | 18.70 | 27.12% | 12.37% | 1.31 | ||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% |
Compare LBRX vs Peers
LB Pharmaceuticals Inc Common Stock (LBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LBRX Income Statement
LB Pharmaceuticals Inc Common Stock (LBRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 81K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -81K▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 33.08M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 8.95M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 1.35M | 7.84M | 51.17M | 23.93M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 200K |
| Operating Income | -2.81M▲ 0% | -11.38M▼ 305.0% | -64.83M▼ 469.9% | -33.16M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -304.98% | -469.88% | - |
| EBITDA | -2.81M | -11.37M | -64.74M | -32.92M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -305.13% | -469.28% | - |
| D&A (Non-Cash Add-back) | 2K | 4K | 91K | 239K |
| EBIT | -12.2M | -1.45M | -63.1M | -30.3M |
| Net Interest Income | -2.08M | -4.01M | 1.72M | 1.75M |
| Interest Income | 73K | 811K | 1.72M | 1.33M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income/Expense | -11.54M | 5.1M | 1.73M | 3.27M |
| Pretax Income | -14.35M▲ 0% | -6.27M▲ 56.3% | -63.1M▼ 905.8% | -29.89M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 1K | 1K | 1K | 0 |
| Effective Tax Rate % | -0.01% | -0.02% | -0% | 0% |
| Net Income | -14.35M▲ 0% | -6.28M▲ 56.3% | -63.1M▼ 905.6% | -29.89M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | 56.27% | -905.61% | - |
| Net Income (Continuing) | -14.35M | -6.28M | -63.1M | -29.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.05▲ 0% | -1.77▲ 56.3% | -17.83▼ 907.3% | -1.18▲ 0% |
| EPS Growth % | - | 56.3% | -907.34% | - |
| EPS (Basic) | -4.05 | -1.77 | -17.83 | - |
| Diluted Shares Outstanding | 3.54M | 3.54M | 3.54M | 25.3M |
| Basic Shares Outstanding | 3.54M | 3.54M | 3.54M | 25.3M |
| Dividend Payout Ratio | - | - | - | - |
LBRX Balance Sheet
LB Pharmaceuticals Inc Common Stock (LBRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 21.49M | 45.63M | 28.88M | 316.4M |
| Cash & Short-Term Investments | 21.4M | 43.29M | 28M | 314.48M |
| Cash Only | 21.4M | 14.98M | 22.98M | 269.74M |
| Short-Term Investments | 0 | 28.31M | 5.02M | 44.73M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 9K | 26K | 132K | 1.92M |
| Total Non-Current Assets | 3K | 23K | 4.66M | 4.34M |
| Property, Plant & Equipment | 3K | 23K | 4.16M | 3.83M |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 512K |
| Other Non-Current Assets | 0 | 0 | 498K | 1.02M |
| Total Assets | 21.49M▲ 0% | 45.66M▲ 112.4% | 33.53M▼ 26.6% | 320.75M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 112.44% | -26.55% | -74.08% |
| Total Current Liabilities | 469K | 2.61M | 8.11M | 6.65M |
| Accounts Payable | 156K | 1.39M | 2.32M | 2.59M |
| Days Payables Outstanding | - | - | - | 5.86K |
| Short-Term Debt | 0 | 0 | 0 | 730K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 221K | 798K | 2.24M | 2.2M |
| Current Ratio | 45.82x | 17.51x | 3.56x | 3.56x |
| Quick Ratio | 45.82x | 17.51x | 3.56x | 3.56x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 49.84M | 77.52M | 119.98M | 3.88M |
| Long-Term Debt | 24.15M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 3.22M | 9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 25.69M | 77.52M | 116.76M | 235.07M |
| Total Liabilities | 50.3M | 80.13M | 128.09M | 10.53M |
| Total Debt | 24.15M | 0 | 3.7M | 3.67M |
| Net Debt | 2.74M | -14.98M | -19.27M | -266.08M |
| Debt / Equity | - | - | - | 0.01x |
| Debt / EBITDA | - | - | - | -0.11x |
| Net Debt / EBITDA | - | - | - | 8.08x |
| Interest Coverage | -1.31x | -2.36x | - | - |
| Total Equity | -28.81M▲ 0% | -34.47M▼ 19.6% | -94.55M▼ 174.3% | 310.22M▲ 0% |
| Equity Growth % | - | -19.65% | -174.28% | 120.59% |
| Book Value per Share | -8.14 | -9.74 | -26.71 | 12.26 |
| Total Shareholders' Equity | -28.81M | -34.47M | -94.55M | 310.22M |
| Common Stock | 1K | 1K | 1K | 3K |
| Retained Earnings | -34.95M | -41.22M | -104.32M | -118.06M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 274K | 111K | -53K |
| Minority Interest | 0 | 0 | 0 | 0 |
LBRX Cash Flow Statement
LB Pharmaceuticals Inc Common Stock (LBRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -2.73M | -12.09M | -53.05M | -53.05M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -343.33% | -338.66% | 28.28% |
| Net Income | -14.35M | -6.28M | -63.1M | -29.89M |
| Depreciation & Amortization | 2K | 4K | 91K | 239K |
| Stock-Based Compensation | 431K | 295K | 3.16M | 1.92M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.1M | -4.8M | 3.48M | -5.63M |
| Working Capital Changes | 86K | -1.31M | 3.31M | 6.68M |
| Change in Receivables | 0 | -154K | 114K | -208K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 |
| Cash from Investing | 123K | -28.01M | 23.23M | -65.91M |
| Capital Expenditures | 0 | -25K | -769K | -59K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 5M |
| Cash from Financing | 22.96M | 33.68M | 38.31M | 342.02M |
| Debt Issued (Net) | 25M | 725K | 0 | 0 |
| Equity Issued (Net) | 903K | 1000K | 1000K | 1.25M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | -2.95M | -2.05M | -1.69M | 301.78M |
| Net Change in Cash | 20.36M▲ 0% | -6.42M▼ 131.6% | 8.5M▲ 232.2% | 258.18M▲ 0% |
| Free Cash Flow | -2.73M▲ 0% | -12.12M▼ 344.2% | -53.82M▼ 344.1% | -26.74M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -344.24% | -344.1% | - |
| FCF per Share | -0.77 | -3.42 | -15.21 | -15.21 |
| FCF Conversion (FCF/Net Income) | 0.19x | 1.93x | 0.84x | 0.89x |
| Interest Paid | 0 | 1.98M | 0 | 0 |
| Taxes Paid | 1K | 1K | 1K | 0 |
LBRX Key Ratios
LB Pharmaceuticals Inc Common Stock (LBRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -71.89% |
| Return on Invested Capital (ROIC) | - | - | 71.91% |
| Debt / Equity | - | - | 0.01x |
| Interest Coverage | -2.36x | - | - |
| FCF Conversion | 1.93x | 0.84x | 0.89x |
LBRX Frequently Asked Questions
LB Pharmaceuticals Inc Common Stock (LBRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
LB Pharmaceuticals Inc Common Stock (LBRX) grew revenue by 0.0% over the past year. Growth has been modest.
LB Pharmaceuticals Inc Common Stock (LBRX) reported a net loss of $29.9M for fiscal year 2024.
Dividend & Returns
LB Pharmaceuticals Inc Common Stock (LBRX) had negative free cash flow of $26.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More LBRX
LB Pharmaceuticals Inc Common Stock (LBRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates